A
Alcista
Alcista · 25%MRVI
$2.69
Precio del escenario
$6.790
-0.269 (-3.96%)Al cierre
Loading chart…
- Máximo
- 7.080
- Apertura
- 7.050
- Precio medio ponderado por volumen
- 6.87
- Volumen
- 2.24M
- Capitalización
- 940.44M
- Mínimo
- 6.735
- Importe
- 15.38M
- EV/EBITDA, TTM
- -276.57
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Its segments include TriLink and Cygnus. Its TriLink segment provides nucleic acid products and related services, including messenger ribonucleic acid (mRNA), oligonucleotides, CleanCap mRNA capping technology, ModTail poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, enzymes, and mRNA manufacturing services. Its Cygnus segment provides biologics safety testing products and services, including host cell protein enzyme-linked immunosorbent assay (ELISA) kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services. Its TriLink and Cygnus segments produce materials used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products.
Análisis de IA of Maravai LifeSciences Holdings Inc (MRVI)
ComprarMaravai LifeSciences Holdings Inc is a good buy right now, trading at $7.44, which is below the average analyst target price of $8.33. The stock has shown a significant year-to-date change of +118.82%, indicating strong momentum. However, the main risk is its forward P/E ratio of 370.37, suggesting that the stock may be overvalued if earnings do not improve significantly in the future.
Métricas de valoración
El PER previsto actual de Maravai LifeSciences Holdings Inc (MRVI) es 370.37, frente a su media de 5 años de 1215.09.
Escenarios de precio de Alphio AI para MRVI
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con MRVI en cartera
Cronología de eventos
Noticias
6.010-05CNBCMorgan Stanley Upgrades Wells Fargo to Overweight, Citing Growth Potential
6.009-25NASDAQ.COMMaravai LifeSciences Stock Surpasses Analyst Target Price
8.508-19stocktwitsMerck and Moderna Announce Successful Cancer Vaccine Trial Results
9.508-06seekingalphaMaravai Reports Q2 Earnings Beat with Revenue Growth
7.507-24NASDAQ.COMBiotech Stocks Reach 52-Week Highs Following Key Catalysts
Preguntas frecuentes sobre MRVI, respondidas por Alphio AI
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Its segments include TriLink and Cygnus. Its TriLink segment provides nucleic acid products and related services, including messenger ribonucleic acid (mRNA), oligonucleotides, CleanCap mRNA capping technology, ModTail poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, enzymes, and mRNA manufacturing services. Its Cygnus segment provides biologics safety testing products and services, including host cell protein enzyme-linked immunosorbent assay (ELISA) kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services. Its TriLink and Cygnus segments produce materials used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Maravai LifeSciences Holdings Inc is a good buy right now, trading at $7.44, which is below the average analyst target price of $8.33. The stock has shown a significant year-to-date change of +118.82%, indicating strong momentum. However, the main risk is its forward P/E ratio of 370.37, suggesting that the stock may be overvalued if earnings do not improve significantly in the future.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.